OmniAb Gestion
Gestion contrôle des critères 2/4
Le PDG OmniAb est Matt Foehr, nommé en Nov2022, a un mandat de 3.5 ans. La rémunération annuelle totale est $ 3.65M, composée du salaire de 16.3% et des bonus 83.7%, y compris les actions et options de la société. détient directement 3.05% des actions de la société, d'une valeur de $ 6.14M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.4 ans et 3.5 ans.
Informations clés
Matt Foehr
Directeur général
US$3.6m
Rémunération totale
| Pourcentage du salaire du PDG | 16.29% |
| Durée du mandat du directeur général | 3.5yrs |
| Propriété du PDG | 3.1% |
| Durée moyenne d'occupation des postes de direction | 3.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.5yrs |
Mises à jour récentes de la gestion
Recent updates
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
Oct 10
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
Aug 09Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
Jul 09OmniAb: Too Much Risk, Not Enough Reward
May 12Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
May 11OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Apr 20
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 15Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Sep 14Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Jul 15The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Mar 26Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
Feb 28OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 15Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
Nov 11Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
Aug 13OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
May 14Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$65m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$64m |
| Mar 31 2025 | n/a | n/a | -US$61m |
| Dec 31 2024 | US$4m | US$594k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$62m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$3m | US$564k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$7m | US$542k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$5m | US$519k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$3m | US$504k | -US$18m |
Rémunération vs marché: La rémunération totale de Matt ($USD 3.65M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.61M ).
Rémunération et revenus: La rémunération de Matt a augmenté alors que l'entreprise n'est pas rentable.
PDG
Matt Foehr (52 yo)
Mr. Matthew W. Foehr, also known as Matt, has been the President, Chief Executive Officer and Director of OmniAb, Inc. since November 1, 2022. Mr. Foehr has been the Chief Executive Officer and President a...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 3.5yrs | US$3.65m | 3.05% $ 6.1m | |
| Executive VP of Finance & CFO | 3.5yrs | US$1.67m | 0.18% $ 363.5k | |
| Chief Legal Officer & Secretary | 3.5yrs | US$1.69m | 0.28% $ 554.7k | |
| Senior Vice President of People & Talent | 3.3yrs | pas de données | pas de données | |
| Senior Vice President of Antibody Discovery | no data | pas de données | pas de données | |
| Senior Vice President of Antibody Technologies | no data | pas de données | pas de données | |
| Senior Vice President of Exploratory Research | 1.3yrs | pas de données | pas de données | |
| Senior Vice President of Discovery Systems | less than a year | pas de données | pas de données | |
| Vice President of Business Development & Strategy | no data | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de OABI est considérée comme expérimentée (ancienneté moyenne 3.4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 3.5yrs | US$3.65m | 3.05% $ 6.1m | |
| Chairman | 3.5yrs | US$258.04k | 2.03% $ 4.1m | |
| Independent Director | 3.5yrs | US$254.71k | 0.064% $ 129.7k | |
| Independent Director | 2.5yrs | US$248.36k | 0.050% $ 99.6k | |
| Independent Director | 1.1yrs | pas de données | 0.0092% $ 18.5k | |
| Independent Director | 1.1yrs | pas de données | 0.0092% $ 18.5k | |
| Independent Director | 3.5yrs | US$254.89k | 0.11% $ 214.3k |
Conseil d'administration expérimenté: Les membres du conseil d'administration de OABI sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/01 00:41 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
OmniAb, Inc. est couverte par 9 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |